Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells 9,233 Shares of Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 9,233 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $3.41, for a total value of $31,484.53. Following the sale, the chief executive officer now directly owns 3,785,350 shares of the company’s stock, valued at approximately $12,908,043.50. This represents a 0.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Checkpoint Therapeutics Trading Up 7.0 %

Shares of CKPT stock opened at $3.35 on Thursday. The stock has a 50 day simple moving average of $3.38 and a 200-day simple moving average of $3.00. The company has a market cap of $163.58 million, a price-to-earnings ratio of -1.82 and a beta of 1.36. Checkpoint Therapeutics, Inc. has a 12-month low of $1.38 and a 12-month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). On average, equities analysts forecast that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. D. Boral Capital started coverage on shares of Checkpoint Therapeutics in a research report on Monday, January 13th. They set a “buy” rating and a $9.00 price objective for the company. Finally, Lake Street Capital raised their target price on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 16th.

Hedge Funds Weigh In On Checkpoint Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CKPT. Magnus Financial Group LLC grew its position in Checkpoint Therapeutics by 12.9% during the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after buying an additional 4,000 shares during the period. PUREfi Wealth LLC purchased a new stake in shares of Checkpoint Therapeutics during the 4th quarter worth approximately $32,000. SBI Securities Co. Ltd. acquired a new stake in shares of Checkpoint Therapeutics in the 4th quarter worth approximately $32,000. PVG Asset Management Corp increased its stake in Checkpoint Therapeutics by 9.2% in the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after purchasing an additional 12,676 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Checkpoint Therapeutics during the third quarter worth $30,000. 22.00% of the stock is owned by institutional investors and hedge funds.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.